您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Covance Reports Second Quarter Revenue of $475M and EPS of $0.49; Updates Full-Year Financial Targets(5)
本文章共23214字,分15页,当前第5页,快速翻页:


 


  Financial Exhibits Follow

                        COVANCE INC.
                CONSOLIDATED INCOME STATEMENTS
  FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2010 AND 2009
        (Dollars in thousands, except per share data)
                          (UNAUDITED)

                                              Three Months Ended June
                                                        30
                                            ------------------------
                                                2010            2009
                                                ----            ----
  Net revenues                              $475,171        $466,049
  Reimbursable out-of-pocket expenses          25,548          23,226
      Total revenues                        500,719        489,275
                                              -------        -------
  Costs and expenses:
    Cost of revenue                          331,360        313,210
    Reimbursable out-of-pocket expenses        25,548          23,226
    Selling, general and administrative        75,045          69,569
    Depreciation and amortization              26,256          23,273
          Total costs and expenses            458,209        429,278
                                              -------        -------

 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Commonwealth Biotechnologies, Inc. Provi

Quintiles Announces New European Headqua

FDA Approves Drug for Chronic Drooling i

Abbott's Simcor ( niacin extended-releas

Abraxis BioScience and Specialised Thera

Shionogi Inc. Announces FDA Approval of

Researchers Solve Mystery of Uner Tan Sy

WaferGen Announces Purchase of SmartChip

Plant Compound Resveratrol Shown to Supp

New pathway to Parkinson's and Alzheimer

deCODE Shows how Genetic Risk of Kidney

相关评论

    
本文章所属分类:首页 研发动态